Table 2.
Design of trials included in the systematic review and meta-analysis
| Source | Blinding | Intervention | Control | Follow-up (month) | Lifestyle intervention | Jadad score |
|---|---|---|---|---|---|---|
| BIP study [8] (2000) |
Double |
Bezafibrate 400 mg daily |
Placebo |
74.4 |
Yes |
4 |
| VA-HIT study [10] (1999) |
Double |
Gemfibrozil 1200 mg daily |
Placebo |
36–60 |
Yes |
4 |
| Acheson J [17] (1972) |
Open |
Clofibrate 1–2 g daily |
Corn oil then placebo |
104 in treatment group 91 in placebo group |
NR |
0 |
| Veterans Administration Cooperative Study Group [18] (1973) |
Double |
Clofibrate 2 g daily |
Placebo |
54 |
NR |
1 |
| Coronary Drug Project Research Group [19] (1975) |
Double |
Clofibrate 1.8 g daily |
Placebo |
74.4 |
NR |
4 |
| WHO-COOP committee of principal Investigators [20] (1978) |
Double |
Clofibrate 1.6 g daily |
Olive oil Placebo |
63.6 |
Yes |
2 |
| LEADER study [21,22] (2002) |
Double |
Bezafibrate 400 mg daily |
Placebo |
55.2 |
NR |
2 |
| E J Whitney [23] (2005) |
Double |
Gemfibrozil 600 mg daily |
Placebo |
30 |
Yes |
3 |
| FIELD study [24] (2005) |
Double |
Fenofibrate 200 mg daily |
Placebo |
60 |
Yes |
4 |
| The ACCORD Study Group [25] (2010) | Double | Fenofibrate 160 mg daily | Placebo | 56.4 | Yes | 4 |